Publications by authors named "Dina O Eriksen"
Article Synopsis
- Active surveillance for cervical intraepithelial neoplasia grade 2 (CIN2) has been increasingly used in Denmark, focusing on women of reproductive age, and aims to evaluate clinical and socioeconomic factors influencing management methods.
- A nationwide study analyzed data from 27,536 women diagnosed with CIN2 between 1998 and 2020, revealing that younger, HPV-vaccinated women were more likely to undergo active surveillance compared to those who had a large loop excision (LLETZ).
- The trend showed a significant rise in active surveillance from 21.7% in 2004 to 73.6% in 2019, although the proportion of younger women opting for this method decreased over time.
Importance: Active surveillance for cervical intraepithelial neoplasia grade 2 (CIN2) is being implemented in many high-income countries due to the association of excisional treatment with preterm birth. However, it is unknown whether active surveillance results in lower risk of preterm birth given that cervical dysplasia itself is associated with higher risk of preterm birth.
Objective: To compare the preterm birth risk between women with CIN2 undergoing active surveillance or immediate loop electrosurgical excision procedure (LEEP).
Background: Cervical intraepithelial neoplasia grade 2 has historically been the threshold for surgical excision, but because of high regression rates, many countries are transitioning to active surveillance. However, estimates for regression rates are based on small studies with heterogeneous definitions of regression and progression.
Objective: This study aimed to describe regression and progression rates of cervical intraepithelial neoplasia grade 2 using nationwide healthcare registry data.
Immunocompromised women are at increased risk of having HPV detected and developing HPV-related diseases such as genital warts, anogenital dysplasia, and cancer. This review aims to summarize the current literature regarding the immunogenicity of the HPV vaccine in immunocompromised women and to discuss whether HPV vaccination may be able to reduce the risk of cervical dysplasia and cancer. HPV vaccination induces an immune response in these women; however, it is unknown whether vaccination is effective in reducing the risk of cervical dysplasia and cancer.
View Article and Find Full Text PDFHPV vaccination is associated with a reduced risk of cervical cancer and its precursors, with greatest protection when the vaccine is administered before sexual debut. This review aims to discuss whether immunization with the nonavalent HPV vaccine should be recommended to women who have previously been vaccinated with the bi- or quadrivalent HPV vaccine and to women who have previously undergone treatment for condylomas or dysplasia of the vulva, vagina, or cervix.
View Article and Find Full Text PDFArticle Synopsis
- This review and meta-analysis investigated the effectiveness of HPV vaccination given after excisional treatment for cervical intraepithelial neoplasia (CIN) in reducing recurrence rates of CIN grade 2 or higher (CIN2+).
- A systematic search of literature included nine studies involving nearly 20,000 women, of which two were randomized controlled trials (RCTs) and seven were observational studies.
- The results showed that HPV vaccination significantly reduced the risk of CIN2+ recurrence, with unadjusted odds ratios indicating a 65% lower risk, although many studies had serious biases affecting quality.